Drug Combination Details
| General Information of the Combination (ID: C25168) | |||||
|---|---|---|---|---|---|
| Name | Camptothecin NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CTNNB1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | 4T1 | CVCL_0125 | Malignant neoplasms | Mus musculus | ||
| BT-474 | CVCL_0179 | Invasive breast carcinoma | Homo sapiens | |||
| In-vivo Model | Tumor inoculation was achieved by subcutaneously injecting 5*104 4T1 cells in the abdominal mammary gland of female BALB/c mice in order to prevent interference with normal bodily functions | |||||
| Experimental
Result(s) |
Camptothecin-doxorubicin combinations showed synergistic antitumor acitivity. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid. J Control Release. 2015 Jul 28;210:198-207. | |||
